AeroRx Therapeutics, Inc., a clinical-stage biopharmaceutical company developing proprietary nebulized combination therapies ...

New users of LAMA-LABA therapy had a 20% reduction in the rate of first pneumonia hospitalization compared with new users of ICS-LABA (HR, 0.80; 95% CI, 0.75-0.86).

Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371 (14):1285-1294. doi: 10.1056/NEJMoa1407154. 5. Oba Y, Chandran AV, Devasahayam JV.

Lung function was significantly improved with LAMA/LABA therapy compared with patients receiving preoperative LAMA therapy (FEV1, 223.1 mL vs. 130 mL; FEV 1 percent predicted, 10.8% vs. 6.8%).

“We found that long-acting muscarinic antagonist (LAMA)-LABA therapy was associated with a lower risk of COPD exacerbations and a lower risk of pneumonia hospitalizations than inhaled ...

In any case, "Feldman and colleagues' study provides assurance to patients and clinicians when choosing a dry-powder inhaler over a metered-dose inhaler of LABA-LAMA-inhaled corticosteroid in a ...

Source Reference: Vogelmeier C, et al "Stepping down from triple inhaled therapy to a LABA/LAMA fixed-dose combination: data from the German real-life DACCORD COPD cohort" ATS 2022.

Reference Sobieraj DM, Baker WL, Nguyen E, et al. Association of inhaled corticosteroids and long-acting muscarinic antagonists with asthma control in patients with uncontrolled, persistent asthma ...

Newer inhalers such as the once or twice-daily LAMA + LABA combinations, for example, aclidinium + formoterol, umeclidinium + once-daily vilanterol and tiotropium + olodaterol, will advance and ...

Several drugmakers are betting that LABA/LAMA inhalers will become the first choice for chronic obstructive pulmonary disease (COPD), which causes debilitating breathlessness and affects more than ...

They specifically recommend against using a long-acting muscarinic antagonist (LAMA) as monotherapy. They also state that LAMA add-on to ICS/long-acting beta-agonist (LABA) therapy won't help with ...